Etiology of metabolic syndrome and dietary intervention

International Journal of Molecular Sciences

Volumn 20, Issue 1, 2019, Pages

  Xu, Hang ^a   Li, Xiaopeng ^a,b   Adams, Hannah ^a   Kubena, Karen ^a   Guo, Shaodong ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b HUAZHONG AGRICULTURAL UNIVERSITY   (China)

Author keywords

Dietary intervention; Insulin resistance; Metabolic syndrome; Obesity; Personal nutrition

Indexed keywords

CHOLESTEROL; GLUCOSE; GLUCOSE TRANSPORTER 4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; MICRORNA; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR FKHR; TRIACYLGLYCEROL;

AUTOPHAGY; BLOOD PRESSURE; BODY MASS; CARDIORESPIRATORY FITNESS; CARDIOVASCULAR DISEASE; DIET; DIET THERAPY; DISEASE EXACERBATION; EPIGENETICS; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; GLUCOTOXICITY; HEALTH PRACTITIONER; HOMEOSTASIS; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE FLORA; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PHYSICAL ACTIVITY; PREVALENCE; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; WAIST CIRCUMFERENCE; ANIMAL; PROCEDURES;

ANIMALS; DIET THERAPY; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 85059496649     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms20010128     Document Type: Review

References (127)

1. Reaven, G.M. Role of Insulin Resistance in Human Disease. Diabetes 1988, 37, 1595–1607. [CrossRef] [PubMed]
2. Gallagher, E.J.; LeRoith, D.; Karnieli, E. The metabolic syndrome—From insulin resistance to obesity and diabetes. Endocrinol. Metab. Clin. N. Am. 2008, 37, 559–579. [CrossRef] [PubMed]
3. Alberti, K.G.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Fruchart, J.C.; James, W.P.; Loria, C.M.; Smith, S.C., Jr.; et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120, 1640–1645.
4. Reaven, G.M. The metabolic syndrome: Is this diagnosis necessary? Am. J. Clin. Nutr. 2006, 83, 1237–1247. [CrossRef] [PubMed]
5. Ogden, C.L.; Carroll, M.D.; Fryar, C.D.; Flegal, K.M. Prevalence of Obesity Among Adults and Youth: United States, 2011–2014. NCHS Data Brief 2015, 219, 1–8.
6. Obesity and Overweight, Fact Sheet. Available online: http://www.who.int/mediacentre/factsheets/fs311/en/(accessed on 1 August 2018).
7. Ervin, R.B. Prevalence of Metabolic Syndrome among Adults 20 Years of Age and Over, by Sex, Age, Race and Ethnicity, and Body Mass Index: United States, 2003–2006; National Health Statistics Reports; U.S. Department of Health and Human Services: Washington, DC, USA, 2009; pp. 1–7.
8. Aguilar, M.; Bhuket, T.; Torres, S.; Liu, B.; Wong, R.J. Prevalence of the Metabolic Syndrome in the United States, 2003–2012. JAMA 2015, 313, 1973–1974. [CrossRef] [PubMed]
9. Wang, S.; Soni, K.G.; Semache, M.; Casavant, S.; Fortier, M.; Pan, L.; Mitchell, G.A. Lipolysis and the integrated physiology of lipid energy metabolism. Mol. Genet. Metab. 2008, 95, 117–126. [CrossRef] [PubMed]
10. Einhorn, D.; Reaven, G.M.; Cobin, R.H.; Ford, E.; Ganda, O.P.; Handelsman, Y.; Hellman, R.; Jellinger, P.S.; Kendall, D.; Krauss, R.M. American College of Endocrinology Position Statement on the Insulin Resistance Syndrome. Endocr. Pract. 2003, 9, 237–252. [PubMed]
11. Albert, V.; Svensson, K.; Shimobayashi, M.; Colombi, M.; Munoz, S.; Jimenez, V.; Handschin, C.; Bosch, F.; Hall, M.N. mTORC2 sustains thermogenesis via Akt-induced glucose uptake and glycolysis in brown adipose tissue. EMBO Mol. Med. 2016, 8, 232–246. [CrossRef] [PubMed]
12. Alberti, K.G.; Zimmet, P.; Shaw, J. The metabolic syndrome—A new worldwide definition. Lancet 2005, 366, 1059–1062. [CrossRef]
13. Guo, S.D. Insulin signaling, resistance, and metabolic syndrome: Insights from mouse models into disease mechanisms. J. Endocrinol. 2014, 220, T1–T23. [CrossRef] [PubMed]
14. Karnieli, E.; Armoni, M. Transcriptional regulation of the insulin-responsive glucose transporter GLUT4 gene: From physiology to pathology. Am. J. Physiol. Endocrinol. Metab. 2008, 295, E38–E45. [CrossRef] [PubMed]
15. Armoni, M.; Harel, C.; Karnieli, E. Transcriptional regulation of the GLUT4 gene: From PPAR-gamma and FOXO1 to FFA and inflammation. Trends Endocrinol. Metab. 2007, 18, 100–107. [CrossRef] [PubMed]
16. LeRoith, D. Beta-cell dysfunction and insulin resistance in type 2 diabetes—Role of metabolic and genetic abnormalities. Am. J. Med. 2002, 113, 3S–11S. [CrossRef]
17. Weir, G.C.; Laybutt, D.R.; Kaneto, H.; Bonner-Weir, S.; Sharma, A. Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes 2001, 50, S154–S159. [CrossRef] [PubMed]
18. Malin, S.K.; Finnegan, S.; Fealy, C.E.; Filion, J.; Rocco, M.B.; Kirwan, J.P. beta-Cell dysfunction is associated with metabolic syndrome severity in adults. Metab. Syndr. Relat. Disord. 2014, 12, 79–85. [CrossRef] [PubMed]
19. Ramos, J.S.; Dalleck, L.C.; Borrani, F.; Fassett, R.G.; Coombes, J.S. Cardiorespiratory fitness is positively associated with increased pancreatic beta cell function independent of fatness in individuals with the metabolic syndrome: Fitness versus fatness. J. Sci. Med. Sport 2017, 20, 45–49. [CrossRef]
20. Barry, V.W.; Baruth, M.; Beets, M.W.; Durstine, J.L.; Liu, J.; Blair, S.N. Fitness vs. fatness on all-cause mortality: A meta-analysis. Prog. Cardiovasc. Dis. 2014, 56, 382–390. [CrossRef]
21. Lee, D.C.; Sui, X.; Artero, E.G.; Lee, I.M.; Church, T.S.; McAuley, P.A.; Stanford, F.C.; Kohl, H.W., 3rd; Blair, S.N. Long-term effects of changes in cardiorespiratory fitness and body mass index on all-cause and cardiovascular disease mortality in men: The Aerobics Center Longitudinal Study. Circulation 2011, 124, 2483–2490. [CrossRef]
22. De Schutter, A.; Lavie, C.J.; Milani, R.V. The impact of obesity on risk factors and prevalence and prognosis of coronary heart disease-the obesity paradox. Prog. Cardiovasc. Dis. 2014, 56, 401–408. [CrossRef]
23. Han, S.S.; Kim, K.W.; Kim, K.I.; Na, K.Y.; Chae, D.W.; Kim, S.; Chin, H.J. Lean mass index: A better predictor of mortality than body mass index in elderly Asians. J. Am. Geriatr. Soc. 2010, 58, 312–317. [CrossRef]
24. Srikanthan, P.; Karlamangla, A.S. Muscle mass index as a predictor of longevity in older adults. Am. J. Med. 2014, 127, 547–553. [CrossRef]
25. Lee, C.G.; Boyko, E.J.; Nielson, C.M.; Stefanick, M.L.; Bauer, D.C.; Hoffman, A.R.; Dam, T.T.; Lapidus, J.A.; Cawthon, P.M.; Ensrud, K.E.; et al. Mortality risk in older men associated with changes in weight, lean mass, and fat mass. J. Am. Geriatr. Soc. 2011, 59, 233–240. [CrossRef]
26. Kim, B.; Feldman, E.L. Insulin resistance in the nervous system. Trends Endocrinol. Metab. 2012, 23, 133–141. [CrossRef] [PubMed]
27. Fayard, E.; Xue, G.; Parcellier, A.; Bozulic, L.; Hemmings, B.A. Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway. Curr. Top. Microbiol. Immunol. 2010, 346, 31–56. [PubMed]
28. Guo, C.A.; Guo, S. Insulin receptor substrate signaling controls cardiac energy metabolism and heart failure. J. Endocrinol. 2017, 233, R131–R143. [CrossRef] [PubMed]
29. Furtado, L.M.; Somwar, R.; Sweeney, G.; Niu, W.; Klip, A. Activation of the Glucose Transporter GLUT4 by Insulin. Biochem. Cell Biol. 2002, 80, 569–578. [CrossRef]
30. Michelle Furtado, L.; Poon, V.; Klip, A. GLUT4 activation: Thoughts on possible mechanisms. Acta Physiol. Scand. 2003, 178, 287–296. [CrossRef]
31. Houde, V.P.; Brûlé, S.; Festuccia, W.T.; Blanchard, P.-G.; Bellmann, K.; Deshaies, Y.; Marette, A. Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue. Diabetes 2010, 59, 1338–1348. [CrossRef]
32. Zhang, Z.Y.; Dodd, G.T.; Tiganis, T. Protein Tyrosine Phosphatases in Hypothalamic Insulin and Leptin Signaling. Trends Pharm. Sci. 2015, 36, 661–674. [CrossRef]
33. Talchai, C.; Xuan, S.; Lin, H.V.; Sussel, L.; Accili, D. Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure. Cell 2012, 150, 1223–1234. [CrossRef] [PubMed]
34. Cao, J.; Yu, Y.; Zhang, Z.; Chen, X.; Hu, Z.; Tong, Q.; Chang, J.; Feng, X.H.; Lin, X. SCP4 Promotes Gluconeogenesis through FoxO1/3a Dephosphorylation. Diabetes 2017. [CrossRef] [PubMed]
35. Withers, D.J.; Burks, D.J.; Towery, H.H.; Altamuro, S.L.; Flint, C.L.; White, M.F. Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat. Genet. 1999, 23, 32–40. [CrossRef] [PubMed]
36. Everard, A.; Lazarevic, V.; Derrien, M.; Girard, M.; Muccioli, G.G.; Neyrinck, A.M.; Possemiers, S.; Van Holle, A.; François, P.; de Vos, W.M.; et al. Responses of Gut Microbiota and Glucose and Lipid Metabolism to Prebiotics in Genetic Obese and Diet-Induced Leptin-Resistant Mice. Diabetes 2011, 60, 2775–2786. [CrossRef] [PubMed]
37. Soleimani, M. Insulin resistance and hypertension: New insights. Kidney Int. 2015, 87, 497–499. [CrossRef]
38. Ryu, J.; Galan, A.K.; Xin, X.; Dong, F.; Abdul-Ghani, M.A.; Zhou, L.; Wang, C.; Li, C.; Holmes, B.M.; Sloane, L.B.; et al. APPL1 Potentiates Insulin Sensitivity by Facilitating the Binding of IRS1/2 to the Insulin Receptor. Cell Rep. 2014, 7, 1227–1238. [CrossRef] [PubMed]
39. Cani, P.D.; Neyrinck, A.M.; Fava, F.; Knauf, C.; Burcelin, R.G.; Tuohy, K.M.; Gibson, G.R.; Delzenne, N.M. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007, 50, 2374–2383. [CrossRef]
40. Shi, Y.; Wang, J.; Chandarlapaty, S.; Cross, J.; Thompson, C.; Rosen, N.; Jiang, X. PTEN is a protein tyrosine phosphatase for IRS1. Nat. Struct. Mol. Biol. 2014, 21, 522–527. [CrossRef]
41. Birnbaum, Y.; Nanhwan, M.K.; Ling, S.; Perez-Polo, J.R.; Ye, Y.; Bajaj, M. PTEN upregulation may explain the development of insulin resistance and type 2 diabetes with high dose statins. Cardiovasc. Drugs 2014, 28, 447–457. [CrossRef]
42. Hakuno, F.; Fukushima, T.; Yoneyama, Y.; Kamei, H.; Ozoe, A.; Yoshihara, H.; Yamanaka, D.; Shibano, T.; Sone-Yonezawa, M.; Yu, B.C.; et al. The Novel Functions of High-Molecular-Mass Complexes Containing Insulin Receptor Substrates in Mediation and Modulation of Insulin-Like Activities: Emerging Concept of Diverse Functions by IRS-Associated Proteins. Front. Endocrinol. 2015, 6, 73. [CrossRef]
43. Sorokin, A.V.; Chen, J. MEMO1, a new IRS1-interacting protein, induces epithelial-mesenchymal transition in mammary epithelial cells. Oncogene 2013, 32, 3130–3138. [CrossRef] [PubMed]
44. Fukushima, T.; Okajima, H.; Yamanaka, D.; Ariga, M.; Nagata, S.; Ito, A.; Yoshida, M.; Asano, T.; Chida, K.; Hakuno, F.; et al. HSP90 interacting with IRS-2 is involved in cAMP-dependent potentiation of IGF-I signals in FRTL-5 cells. Mol. Cell. Endocrinol. 2011, 344, 81–89. [CrossRef] [PubMed]
45. Fukushima, T.; Yoshihara, H.; Furuta, H.; Kamei, H.; Hakuno, F.; Luan, J.; Duan, C.; Saeki, Y.; Tanaka, K.; Iemura, S.; et al. Nedd4-induced monoubiquitination of IRS-2 enhances IGF signalling and mitogenic activity. Nat. Commun. 2015, 6, 6780. [CrossRef] [PubMed]
46. Kubota, N.; Tobe, K.; Terauchi, Y.; Eto, K.; Yamauchi, T.; Suzuki, R.; Tsubamoto, Y.; Komeda, K.; Nakano, R.; Miki, H.; et al. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes 2000, 49, 1880–1889. [CrossRef] [PubMed]
47. Withers, D.J.; Gutierrez, J.S.; Towery, H.; Burks, D.J.; Ren, J.; Previs, S.; Zhang, Y.; Bernal, D.; Pons, S.; Shulman, G.; et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998, 391, 900–904. [CrossRef]
48. Araki, E.; Lipes, M.A.; Patti, M.-E.; Brüning, J.C.; Haag III, B.; Johnson, R.S.; Kahn, C.R. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 1994, 372, 186–190. [CrossRef] [PubMed]
49. Arnold, S.E.; Lucki, I.; Brookshire, B.R.; Carlson, G.C.; Browne, C.A.; Kazi, H.; Bang, S.; Choi, B.R.; Chen, Y.; McMullen, M.F.; et al. High fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behavior in mice. Neurobiol. Dis. 2014, 67, 79–87. [CrossRef]
50. Parvaiz, F.; Manzoor, S.; Iqbal, J.; Sarkar-Dutta, M.; Imran, M.; Waris, G. Hepatitis C virus NS5A promotes insulin resistance through IRS-1 serine phosphorylation and increased gluconeogenesis. World J. Gastroenterol. 2015, 21, 12361–12369. [CrossRef]
51. Sayaka Katagiri, K.P.; Maeda, Y.; Rao, T.N.; Khamaisi, M.; Li, Q.; Yokomizo, H.; Mima, A.; Lancerotto, L.; Wagers, A.; Orgill, D.P.; et al. Overexpressing IRS1 in Endothelial Cells Enhances Angioblast Differentiation and Wound Healing in Diabetes and Insulin Resistance. Diabetes 2016, 65, 2760–2771. [CrossRef]
52. Giacco, F.; Brownlee, M. Oxidative Stress and Diabetic Complications. Circ. Res. 2010, 107, 1058–1070. [CrossRef]
53. Motohashi, N.; Alexander, M.S.; Shimizu-Motohashi, Y.; Myers, J.A.; Kawahara, G.; Kunkel, L.M. Regulation of IRS1/Akt insulin signaling by microRNA-128a during myogenesis. J. Cell Sci. 2013, 126, 2678–2691. [CrossRef] [PubMed]
54. Wang, Y.; Hu, C.; Cheng, J.; Chen, B.; Ke, Q.; Lv, Z.; Wu, J.; Zhou, Y. MicroRNA-145 suppresses hepatocellular carcinoma by targeting IRS1 and its downstream Akt signaling. Biochem. Biophys. Res. Commun. 2014, 446, 1255–1260. [CrossRef] [PubMed]
55. Fernandez-Twinn, D.S.; Alfaradhi, M.Z.; Martin-Gronert, M.S.; Duque-Guimaraes, D.E.; Piekarz, A.; Ferland-McCollough, D.; Bushell, M.; Ozanne, S.E. Downregulation of IRS-1 in adipose tissue of offspring of obese mice is programmed cell-autonomously through post-transcriptional mechanisms. Mol. Metab. 2014, 3, 325–333. [CrossRef] [PubMed]
56. Kubota, N.; Terauchi, Y.; Tobe, K.; Yano, W.; Suzuki, R.; Ueki, K.; Takamoto, I.; Satoh, H.; Maki, T.; Kubota, T.; et al. Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J. Clin. Investig. 2004, 114, 917–927. [CrossRef] [PubMed]
57. Hashimoto, S.; Kubota, N.; Sato, H.; Sasaki, M.; Takamoto, I.; Kubota, T.; Nakaya, K.; Noda, M.; Ueki, K.; Kadowaki, T. Insulin receptor substrate-2 (Irs2) in endothelial cells plays a crucial role in insulin secretion. Diabetes 2015, 64, 876–886. [CrossRef] [PubMed]
58. Park, K.; Li, Q.; Rask-Madsen, C.; Mima, A.; Mizutani, K.; Winnay, J.; Maeda, Y.; D’Aquino, K.; White, M.F.; Feener, E.P.; et al. Serine phosphorylation sites on IRS2 activated by angiotensin II and protein kinase C to induce selective insulin resistance in endothelial cells. Mol. Cell. Biol. 2013, 33, 3227–3241. [CrossRef]
59. Neukamm, S.S.; Ott, J.; Dammeier, S.; Lehmann, R.; Haring, H.U.; Schleicher, E.; Weigert, C. Phosphorylation of serine 1137/1138 of mouse insulin receptor substrate (IRS) 2 regulates cAMP-dependent binding to 14-3-3 proteins and IRS2 protein degradation. J. Biol. Chem. 2013, 288, 16403–16415. [CrossRef]
60. Day, E.; Poulogiannis, G.; McCaughan, F.; Mulholland, S.; Arends, M.J.; Ibrahim, A.E.; Dear, P.H. IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer. Int. J. Exp. Pathol. 2013, 94, 203–211.
61. Guo, S. Molecular Basis of Insulin Resistance: The Role of IRS and Foxo1 in the Control of Diabetes Mellitus and Its Complications. Drug Discov. Today Dis. Mech. 2013, 10, e27–e33. [CrossRef]
62. Allison, M.B.; Myers, M.G., Jr. 20 years of leptin: Connecting leptin signaling to biological function. J. Endocrinol. 2014, 223, T25–T35. [CrossRef]
63. Morris, D.L.; Rui, L.Y. Recent advances in understanding leptin signaling and leptin resistance. Am. J. Physiol. Endocrinol. Metab. 2009, 297, E1247–E1259. [CrossRef]
64. Myers, M.G.; Cowley, M.A.; Münzberg, H. Mechanisms of Leptin Action and Leptin Resistance. Annu. Rev. Physiol. 2008, 70, 537–556. [CrossRef] [PubMed]
65. Yiannikouris, F.; Karounos, M.; Charnigo, R.; English, V.L.; Rateri, D.L.; Daugherty, A.; Cassis, L.A. Adipocyte-specific deficiency of angiotensinogen decreases plasma angiotensinogen concentration and systolic blood pressure in mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012, 302, R244–R251. [CrossRef] [PubMed]
66. Su, W.; Guo, Z.; Randall, D.C.; Cassis, L.; Brown, D.R.; Gong, M.C. Hypertension and disrupted blood pressure circadian rhythm in type 2 diabetic db/db mice. Am. J. Physiol. Heart Circ. Physiol. 2008, 295, H1634–H1641. [CrossRef] [PubMed]
67. Qi, Y.; Zhang, K.; Wu, Y.; Xu, Z.; Yong, Q.C.; Kumar, R.; Baker, K.M.; Zhu, Q.; Chen, S.; Guo, S. Novel mechanism of blood pressure regulation by forkhead box class O1-mediated transcriptional control of hepatic angiotensinogen. Hypertension 2014, 64, 1131–1140. [CrossRef] [PubMed]
68. Rani, V.; Deep, G.; Singh, R.K.; Palle, K.; Yadav, U.C. Oxidative stress and metabolic disorders: Pathogenesis and therapeutic strategies. Life Sci. 2016, 148, 183–193. [CrossRef] [PubMed]
69. Murphy, M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009, 417, 1–13. [CrossRef] [PubMed]
70. Yecies, J.L.; Zhang, H.H.; Menon, S.; Liu, S.; Yecies, D.; Lipovsky, A.I.; Gorgun, C.; Kwiatkowski, D.J.; Hotamisligil, G.S.; Lee, C.-H.; et al. Akt Stimulates Hepatic SREBP1c and Lipogenesis through Parallel mTORC1-Dependent and Independent Pathways. Cell Metab. 2011, 14, 280. [CrossRef]
71. Jiang, F.; Lim, H.K.; Morris, M.J.; Prior, L.; Velkoska, E.; Wu, X.; Dusting, G.J. Systemic upregulation of NADPH oxidase in diet-induced obesity in rats. Redox Rep. 2011, 16, 223–229. [CrossRef]
72. Yang, X.; Ongusaha, P.P.; Miles, P.D.; Havstad, J.C.; Zhang, F.; So, W.V.; Kudlow, J.E.; Michell, R.H.; Olefsky, J.M.; Field, S.J.; et al. Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature 2008, 451, 964–969. [CrossRef]
73. Guinez, C.; Filhoulaud, G.; Rayah-Benhamed, F.; Marmier, S.; Dubuquoy, C.; Dentin, R.; Moldes, M.; Burnol, A.F.; Yang, X.; Lefebvre, T.; et al. O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver. Diabetes 2011, 60, 1399–1413. [CrossRef] [PubMed]
74. Andersen, C.J.; Murphy, K.E.; Fernandez, M.L. Impact of Obesity and Metabolic Syndrome on Immunity. Adv. Nutr. 2016, 7, 66–75. [CrossRef] [PubMed]
75. Guilherme, A.; Virbasius, J.V.; Puri, V.; Czech, M.P. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 2008, 9, 367–377. [CrossRef] [PubMed]
76. Winer, S.; Chan, Y.; Paltser, G.; Truong, D.; Tsui, H.; Bahrami, J.; Dorfman, R.; Wang, Y.; Zielenski, J.; Mastronardi, F.; et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat. Med. 2009, 15, 921–929. [CrossRef] [PubMed]
77. Bremer, A.A.; Devaraj, S.; Afify, A.; Jialal, I. Adipose tissue dysregulation in patients with metabolic syndrome. J. Clin. Endocrinol. Metab. 2011, 96, E1782–E1788. [CrossRef] [PubMed]
78. Xu, H.; Li, H.; Woo, S.L.; Kim, S.M.; Shende, V.R.; Neuendorff, N.; Guo, X.; Guo, T.; Qi, T.; Pei, Y.; et al. Myeloid cell-specific disruption of Period1 and Period2 exacerbates diet-induced inflammation and insulin resistance. J. Biol. Chem. 2014, 289, 16374–16388. [CrossRef]
79. Cheng, Z.; Guo, S.; Copps, K.; Dong, X.; Kollipara, R.; Rodgers, J.T.; Depinho, R.A.; Puigserver, P.; White, M.F. Foxo1 integrates insulin signaling with mitochondrial function in the liver. Nat. Med. 2009, 15, 1307–1311. [CrossRef] [PubMed]
80. Jais, A.; Einwallner, E.; Sharif, O.; Gossens, K.; Lu, T.T.; Soyal, S.M.; Medgyesi, D.; Neureiter, D.; Paier-Pourani, J.; Dalgaard, K.; et al. Heme oxygenase-1 drives metaflammation and insulin resistance in mouse and man. Cell 2014, 158, 25–40. [CrossRef]
81. Jialal, I.; Kaur, H.; Devaraj, S. Toll-like receptor status in obesity and metabolic syndrome: A translational perspective. J. Clin. Endocrinol. Metab. 2014, 99, 39–48. [CrossRef]
82. Catrysse, L.; van Loo, G. Inflammation and the Metabolic Syndrome: The Tissue-Specific Functions of NF-kappaB. Trends Cell Biol. 2017, 27, 417–429. [CrossRef]
83. Botchlett, R.; Woo, S.L.; Liu, M.; Pei, Y.; Guo, X.; Li, H.; Wu, C. Nutritional approaches for managing obesity-associated metabolic diseases. J. Endocrinol. 2017, 233, R145–R171. [CrossRef] [PubMed]
84. Calder, P.C. Omega-3 Fatty Acids and Inflammatory Processes. Nutrients 2010, 2, 355–374. [CrossRef]
85. Oh, D.Y.; Talukdar, S.; Bae, E.J.; Imamura, T.; Morinaga, H.; Fan, W.; Li, P.; Lu, W.J.; Watkins, S.M.; Olefsky, J.M. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142, 687–698. [CrossRef] [PubMed]
86. Itariu, B.K.; Zeyda, M.; Hochbrugger, E.E.; Neuhofer, A.; Prager, G.; Schindler, K.; Bohdjalian, A.; Mascher, D.; Vangala, S.; Schranz, M.; et al. Long-chain n-3 PUFAs reduce adipose tissue and systemic inflammation in severely obese nondiabetic patients: A randomized controlled trial. Am. J. Clin. Nutr. 2012, 96, 1137–1149. [CrossRef] [PubMed]
87. Spencer, M.; Finlin, B.S.; Unal, R.; Zhu, B.; Morris, A.J.; Shipp, L.R.; Lee, J.; Walton, R.G.; Adu, A.; Erfani, R.; et al. Kern. Omega-3 Fatty Acids Reduce Adipose Tissue Macrophages in Human Subjects With Insulin Resistance. Diabetes 2013, 62, 1709–1717. [CrossRef] [PubMed]
88. Bi, X.; Li, F.; Liu, S.; Jin, Y.; Zhang, X.; Yang, T.; Dai, Y.; Li, X.; Zhao, A.Z. omega-3 polyunsaturated fatty acids ameliorate type 1 diabetes and autoimmunity. J. Clin. Investig. 2017, 127, 1757–1771. [CrossRef] [PubMed]
89. Garaulet, M.; Madrid, J.A. Chronobiological aspects of nutrition, metabolic syndrome and obesity. Adv. Drug Deliv. Rev. 2010, 62, 967–978. [CrossRef]
90. Turek, F.W.; Joshu, C.; Kohsaka, A.; Lin, E.; Ivanova, G.; McDearmon, E.; Laposky, A.; Losee-Olson, S.; Easton, A.; Jensen, D.R.; et al. Obesity and metabolic syndrome in circadian Clock mutant mice. Science 2005, 308, 1043–1045. [CrossRef]
91. Chaves, I.; van der Horst, G.T.J.; Schellevis, R.; Nijman, R.M.; Koerkamp, M.G.; Holstege, F.C.P.; Smidt, M.P.; Hoekman, M.F.M. Insulin-FOXO3 Signaling Modulates Circadian Rhythms via Regulation of Clock Transcription. Curr. Biol. 2014, 24, 1248–1255. [CrossRef]
92. Rudic, R.D.; McNamara, P.; Curtis, A.M.; Boston, R.C.; Panda, S.; Hogenesch, J.B.; FitzGerald, G.A. BMAL1 and CLOCK, two essential components of the circadian clock, are involved in glucose homeostasis. PLoS Biol. 2004, 2, 1893–1899. [CrossRef]
93. Shi, S.-Q.; Ansari, T.S.; McGuinness, O.P.; Wasserman, D.H.; Johnson, C.H. Circadian Disruption Leads to Insulin Resistance and Obesity. Curr. Biol. 2013, 23, 372–381. [CrossRef] [PubMed]
94. Shetty, A.; Hsu, J.W.; Manka, P.P.; Syn, W.K. Role of the Circadian Clock in the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. Dig. Dis. Sci. 2018, 63, 3187–3206. [CrossRef] [PubMed]
95. Kalsbeek, A.; la Fleur, S.; Fliers, E. Circadian control of glucose metabolism. Mol. Metab. 2014, 3, 372–383. [CrossRef] [PubMed]
96. Takahashi, J.S.; Hong, H.-K.; Ko, C.H.; McDearmon, E.L. The genetics of mammalian circadian order and disorder: Implications for physiology and disease. Nat. Rev. Genet. 2008, 9, 764. [CrossRef] [PubMed]
97. Eckel-Mahan, K.L.; Patel, V.R.; de Mateo, S.; Orozco-Solis, R.; Ceglia, N.J.; Sahar, S.; Dilag-Penilla, S.A.; Dyar, K.A.; Baldi, P.; Sassone-Corsi, P. Reprogramming of the Circadian Clock by Nutritional Challenge. Cell 2013, 155, 1464–1478. [CrossRef] [PubMed]
98. Mendoza, J.; Pevet, P.; Challet, E. High-fat feeding alters the clock synchronization to light. J. Physiol. 2008, 586, 5901–5910. [CrossRef] [PubMed]
99. Kohsaka, A.; Laposky, A.D.; Ramsey, K.M.; Estrada, C.; Joshu, C.; Kobayashi, Y.; Turek, F.W.; Bass, J. High-Fat Diet Disrupts Behavioral and Molecular Circadian Rhythms in Mice. Cell Metab. 2007, 6, 414–421. [CrossRef]
100. Young, M.E.; Wilson, C.R.; Razeghi, P.; Guthrie, P.H.; Taegtmeyer, H. Alterations of the circadian clock in the heart by streptozotocin-induced diabetes. J. Mol. Cell. Cardiol. 2002, 34, 223–231. [CrossRef]
101. Fumagalli, M.; Moltke, I.; Grarup, N.; Racimo, F.; Bjerregaard, P.; Jorgensen, M.E.; Korneliussen, T.S.; Gerbault, P.; Skotte, L.; Linneberg, A.; et al. Greenlandic Inuit show genetic signatures of diet and climate adaptation. Science 2015, 349, 1343–1347. [CrossRef]
102. Zheng, J.S.; Parnell, L.D.; Smith, C.E.; Lee, Y.C.; Jamal-Allial, A.; Ma, Y.; Li, D.; Tucker, K.L.; Ordovas, J.M.; Lai, C.Q. Circulating 25-hydroxyvitamin D, IRS1 variant rs2943641, and insulin resistance: Replication of a gene-nutrient interaction in 4 populations of different ancestries. Clin. Chem. 2014, 60, 186–196. [CrossRef]
103. Guo, S.; Cichy, S.B.; He, X.; Yang, Q.; Ragland, M.; Ghosh, A.K.; Johnson, P.F.; Unterman, T.G. Insulin suppresses transactivation by CAAT/enhancer-binding proteins beta (C/EBPbeta). Signaling to p300/CREB-binding protein by protein kinase B disrupts interaction with the major activation domain of C/EBPbeta. J. Biol. Chem. 2001, 276, 8516–8523. [CrossRef] [PubMed]
104. Cao, J.; Peng, J.; An, H.; He, Q.; Boronina, T.; Guo, S.; White, M.F.; Cole, P.A.; He, L. Endotoxemia-mediated activation of acetyltransferase P300 impairs insulin signaling in obesity. Nat. Commun. 2017, 8, 131. [CrossRef] [PubMed]
105. Remely, M.; Haslberger, A.G. The microbial epigenome in metabolic syndrome. Mol. Asp. Med. 2017, 54, 71–77. [CrossRef] [PubMed]
106. Marques, F.Z.; Nelson, E.; Chu, P.Y.; Horlock, D.; Fiedler, A.; Ziemann, M.; Tan, J.K.; Kuruppu, S.; Rajapakse, N.W.; El-Osta, A.; et al. High-Fiber Diet and Acetate Supplementation Change the Gut Microbiota and Prevent the Development of Hypertension and Heart Failure in Hypertensive Mice. Circulation 2017, 135, 964–977. [CrossRef] [PubMed]
107. Chassaing, B.; Miles-Brown, J.; Pellizzon, M.; Ulman, E.; Ricci, M.; Zhang, L.; Patterson, A.D.; Vijay-Kumar, M.; Gewirtz, A.T. Lack of soluble fiber drives diet-induced adiposity in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2015, 309, G528–G541. [CrossRef] [PubMed]
108. Yan, H.; Potu, R.; Lu, H.; Vezzoni de Almeida, V.; Stewart, T.; Ragland, D.; Armstrong, A.; Adeola, O.; Nakatsu, C.H.; Ajuwon, K.M. Dietary fat content and fiber type modulate hind gut microbial community and metabolic markers in the pig. PLoS ONE 2013, 8, e59581. [CrossRef] [PubMed]
109. Wang, J.; Tang, H.; Zhang, C.; Zhao, Y.; Derrien, M.; Rocher, E.; van-Hylckama Vlieg, J.E.; Strissel, K.; Zhao, L.; Obin, M.; et al. Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. ISME J 2015, 9, 1–15. [CrossRef]
110. Hulston, C.J.; Churnside, A.A.; Venables, M.C. Probiotic supplementation prevents high-fat, overfeeding-induced insulin resistance in human subjects. Br. J. Nutr. 2015, 113, 596–602. [CrossRef]
111. Lye, H.S.; Kuan, C.Y.; Ewe, J.A.; Fung, W.Y.; Liong, M.T. The Improvement of Hypertension by Probiotics: Effects on Cholesterol, Diabetes, Renin, and Phytoestrogens. Int. J. Mol. Sci. 2009, 10, 3755–3775. [CrossRef]
112. Guenther Boden, C.H.; Barrero, C.A.; Stein, T.P.; Chen, X.; Cheung, P.; Fecchio, C.; Koller, S.; Merali, S. Excessive caloric intake acutely causes oxidative stress, GLUT4 carbonylation, and insulin resistance in healthy men. Sci. Transl. Med. 2015, 7, 304re307.
113. Raziani, F.; Tholstrup, T.; Kristensen, M.D.; Svanegaard, M.L.; Ritz, C.; Astrup, A.; Raben, A. High intake of regular-fat cheese compared with reduced-fat cheese does not affect LDL cholesterol or risk markers of the metabolic syndrome: A randomized controlled trial. Am. J. Clin. Nutr. 2016, 104, 973–981. [CrossRef] [PubMed]
114. Nilsen, R.; Hostmark, A.T.; Haug, A.; Skeie, S. Effect of a high intake of cheese on cholesterol and metabolic syndrome: Results of a randomized trial. Food Nutr. Res. 2015, 59, 27651. [CrossRef] [PubMed]
115. Thorning, T.K.; Raziani, F.; Bendsen, N.T.; Astrup, A.; Tholstrup, T.; Raben, A. Diets with high-fat cheese, high-fat meat, or carbohydrate on cardiovascular risk markers in overweight postmenopausal women: A randomized crossover trial. Am. J. Clin. Nutr. 2015, 102, 573–581. [CrossRef] [PubMed]
116. Cheng, C.W.; Villani, V.; Buono, R.; Wei, M.; Kumar, S.; Yilmaz, O.H.; Cohen, P.; Sneddon, J.B.; Perin, L.; Longo, V.D. Fasting-Mimicking Diet Promotes Ngn3-Driven beta-Cell Regeneration to Reverse Diabetes. Cell 2017, 168, 775–788. [CrossRef] [PubMed]
117. Li, Y.; Hruby, A.; Bernstein, A.M.; Ley, S.H.; Wang, D.D.; Chiuve, S.E.; Sampson, L.; Rexrode, K.M.; Rimm, E.B.; Willett, W.C.; et al. Saturated Fats Compared With Unsaturated Fats and Sources of Carbohydrates in Relation to Risk of Coronary Heart Disease: A Prospective Cohort Study. J. Am. Coll. Cardiol. 2015, 66, 1538–1548. [CrossRef] [PubMed]
118. Sacks, F.M.; Lichtenstein, A.H.; Wu, J.H.Y.; Appel, L.J.; Creager, M.A.; Kris-Etherton, P.M.; Miller, M.; Rimm, E.B.; Rudel, L.L.; Robinson, J.G.; et al. Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. Circulation 2017, 136, e1–e23. [CrossRef] [PubMed]
119. Finucane, O.M.; Lyons, C.L.; Murphy, A.M.; Reynolds, C.M.; Klinger, R.; Healy, N.P.; Cooke, A.A.; Coll, R.C.; McAllan, L.; Nilaweera, K.N.; et al. Monounsaturated Fatty Acid–Enriched High-Fat Diets Impede Adipose NLRP3 Inflammasome–Mediated IL-1β Secretion and Insulin Resistance Despite Obesity. Diabetes 2015, 64, 2116–2128. [CrossRef]
120. Lynch, C.J.; Adams, S.H. Branched-chain amino acids in metabolic signalling and insulin resistance. Nat. Rev. Endocrinol. 2014, 10, 723–736. [CrossRef]
121. Pinent, M.; Cedo, L.; Montagut, G.; Blay, M.; Ardevol, A. Procyanidins Improve some Disrupted Glucose Homoeostatic Situations: An Analysis of Doses and Treatments According to Different Animal Models. Crit. Rev. Food Sci. Nutr. 2012, 52, 569–584. [CrossRef]
122. Babu, P.V.A.; Liu, D.M.; Gilbert, E.R. Recent advances in understanding the anti-diabetic actions of dietary flavonoids. J. Nutr. Biochem. 2013, 24, 1777–1789. [CrossRef]
123. Li, X.; Sui, Y.; Li, S.; Xie, B.; Sun, Z. A-type procyanidins from litchi pericarp ameliorate hyperglycaemia by regulating hepatic and muscle glucose metabolism in streptozotocin (STZ)-induced diabetic mice fed with high fat diet. J. Funct. Foods 2016, 27, 711–722. [CrossRef]
124. Li, X.; Li, S.; Chen, M.; Wang, J.; Xie, B.; Sun, Z. (-)-Epigallocatechin-3-Gallate (EGCG) inhibits starch digestion and improves glucose homeostasis through direct or indirect activation of PXR/CAR-mediated phase II metabolism in diabetic mice. Food Funct. 2018, 9, 4651–4663. [CrossRef] [PubMed]
125. Blade, C.; Arola, L.; Salvado, M.J. Hypolipidemic effects of proanthocyanidins and their underlying biochemical and molecular mechanisms. Mol. Nutr. Food Res. 2010, 54, 37–59. [CrossRef] [PubMed]
126. Hanhineva, K.; Törrönen, R.; Bondia-Pons, I.; Pekkinen, J.; Kolehmainen, M.; Mykkänen, H.; Poutanen, K. Impact of Dietary Polyphenols on Carbohydrate Metabolism. Int. J. Mol. Sci. 2010, 11, 1365–1402. [CrossRef] [PubMed]
127. Wang, X.; Zhang, W.; Chen, H.; Liao, N.; Wang, Z.; Zhang, X.; Hai, C. High selenium impairs hepatic insulin sensitivity through opposite regulation of ROS. Toxicol. Lett. 2014, 224, 16–23. [CrossRef] [PubMed]